Cryoport Reports $0.25 Per-Share Loss, Raises 2026 Revenue Outlook
Key Facts
Cryoport reported a net loss attributable to common shareholders of $0.25 per share in the third quarter of 2026, compared with a loss of $0.18 in the same period of 2025, according to the company’s results statement published on November 5. Quarterly revenue rose to $50.220 million from $44.233 million a year earlier, an annual increase of 14%. The company also raised its full-year 2026 revenue outlook to between $197 million and $199 million. The results combined revenue growth with a wider loss, as the loss from continuing operations reached $10.852 million, compared with $6.696 million in the third quarter of the previous year. The stock closed at $16.70 in the November 4 session, according to EL7 data.
Revenue growth came from the life sciences segments, with service revenue rising 18% to $28.564 million from $24.258 million a year earlier. Product revenue increased 8% to $21.656 million from $19.975 million in the corresponding period. The chief executive said revenue from commercial cell and gene therapy customers rose 20% year over year during the quarter. BioStorage/BioServices revenue also grew 25%, according to the statement. The figures reflect expansion across more than one activity within the life sciences business, alongside a continued increase in the reported operating loss.
In biopharmaceutical logistics, BioLogistics Solutions revenue rose 16% year over year in the third quarter of 2026. The company attributed the increase to the continued development of commercial therapies and progress in clinical trials in the cell and gene therapy market. In its statement, it said revenue in this business was driven by both factors during the period. This growth came alongside the increases recorded in life sciences services and products. The company thus reported revenue expansion linked to commercial demand and clinical progress, while the loss from continuing operations increased compared with the previous year.
Cryoport supported 788 clinical trials globally as of September 30, 2026, a net increase of 43 trials from the number recorded on the same date in 2025. The portfolio included 99 Phase III trials, according to the results statement. This figure provides context on the company’s reach across clinical programs at different stages, alongside revenue from commercial customers. The company linked BioLogistics Solutions revenue growth to clinical-trial progress and the continued development of commercial therapies in the cell and gene therapy market. This comes as the company raised its annual revenue outlook to $197–199 million for 2026.